Global Tetanus Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tetanus Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus. During childhood five doses are recommended, with a sixth given during adolescence. Additional doses every 10 years are recommended. After three doses almost everyone is initially immune. In those who are not up to date on their tetanus immunization a booster should be given within 48 hours of an injury. In those with high risk injuries who are not fully immunized tetanus antitoxin may also be recommended. Making sure women who are pregnant are up to date on their tetanus immunization and, if not, immunizing them can prevent neonatal tetanus.
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.
Tetanus Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tetanus Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Adult and Pediatric are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tetanus Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Tetanus Vaccine key manufacturers include GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc, Sanofi Pasteur SA, Biological E, Dano Vaccine &Biological Pvt.Ltd.,, Panera and Shantha Biotechnics Ltd, etc. GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc are top 3 players and held % sales share in total in 2022.
Tetanus Vaccine can be divided into Diphtheria and tetanus (DT) vaccines, Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines, Tetanus and diphtheria (Td) vaccines and Tetanus, diphtheria, and pertussis (Tdap) vaccines, etc. Diphtheria and tetanus (DT) vaccines is the mainstream product in the market, accounting for % sales share globally in 2022.
Tetanus Vaccine is widely used in various fields, such as Adult and Pediatric, etc. Adult provides greatest supports to the Tetanus Vaccine industry development. In 2022, global % sales of Tetanus Vaccine went into Adult filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tetanus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
Dano Vaccine &Biological Pvt.Ltd.,
Panera
Shantha Biotechnics Ltd
Segment by Type
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Tetanus, diphtheria, and pertussis (Tdap) vaccines
Adult
Pediatric
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tetanus Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tetanus Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tetanus Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tetanus Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tetanus Vaccine introduction, etc. Tetanus Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Tetanus Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.
Tetanus Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tetanus Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Adult and Pediatric are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tetanus Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Tetanus Vaccine key manufacturers include GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc, Sanofi Pasteur SA, Biological E, Dano Vaccine &Biological Pvt.Ltd.,, Panera and Shantha Biotechnics Ltd, etc. GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc are top 3 players and held % sales share in total in 2022.
Tetanus Vaccine can be divided into Diphtheria and tetanus (DT) vaccines, Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines, Tetanus and diphtheria (Td) vaccines and Tetanus, diphtheria, and pertussis (Tdap) vaccines, etc. Diphtheria and tetanus (DT) vaccines is the mainstream product in the market, accounting for % sales share globally in 2022.
Tetanus Vaccine is widely used in various fields, such as Adult and Pediatric, etc. Adult provides greatest supports to the Tetanus Vaccine industry development. In 2022, global % sales of Tetanus Vaccine went into Adult filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tetanus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
Dano Vaccine &Biological Pvt.Ltd.,
Panera
Shantha Biotechnics Ltd
Segment by Type
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Tetanus, diphtheria, and pertussis (Tdap) vaccines
Segment by Application
Adult
Pediatric
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tetanus Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tetanus Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tetanus Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tetanus Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tetanus Vaccine introduction, etc. Tetanus Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Tetanus Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.